Knight Therapeutics Inc. (TSE:GUD) Most Popular Amongst Individual Investors Who Own 41% of the Shares, Institutions Hold 24%

Yahoo FinanceDec 27 05:28 ET

Knight Therapeutics Says Health Canada Accepts ADHD Drug Application for Review

MT NewswiresDec 16 16:50 ET

Express News | Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (Viloxazine) in Canada

ReutersDec 16 16:30 ET

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree (Viloxazine) in Canada

GlobeNewswireDec 16 16:30 ET

Knight Therapeutics Announces Regulatory Approval of TAVALISSE in Mexico

GlobeNewswireDec 12 07:30 ET

Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript Summary

moomoo AINov 9 06:53 ET · Conference Call